Adjuvant pyrotinib plus capecitabine for tiny HER2 breast cancer
Part of Cancer, Skin clinical trials.
This trial studies whether adding pyrotinib and capecitabine after surgery can lower the risk of cancer coming back in people with very small, lymph-node–negative, HER2-positive breast cancer. It’s for patients who fit specific tumor size and HER2 test results and who can safely take chemotherapy-like medicines and stay on contraception during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 to 70.
- Your breast cancer was removed by surgery and is “tiny” (no larger than 1 mm) with no lymph node spread (N0).
- Your tumor is HER2-positive (either HER2 3+ on the biopsy, or HER2 0–2+ but HER2 amplified on FISH testing).
- Your hormone receptors are low/negative (ER and PR under 1%), or you meet the trial’s hormone-receptor definition for eligibility.
- You must be well enough to take treatment: ECOG 0–1, and blood counts, liver, kidneys, and heart tests meet limits (including QTc < 470 ms and LVEF > 50%).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding pyrotinib after standard treatment helps prevent breast cancer from coming back in people with HER2-positive early-stage breast cancer. You may be eligible if you finished chemotherapy plus trastuzumab and still had signs of cancer in the tissue removed during surgery.
This trial tests whether giving a combination of two targeted drugs (pyrotinib and trastuzumab) along with standard chemotherapy before surgery can work better for HER2-positive breast cancer. It is for women whose cancer has not spread to distant organs and who have not yet had treatment for their cancer.
This study tests whether taking pyrotinib (a daily pill) with capecitabine (another pill) after breast cancer surgery can help prevent HER2-positive early-stage breast cancer from coming back. It is for women who have already had their cancer removed and meet certain risk criteria.
This trial tests a combination of two oral medications, capecitabine (a chemotherapy pill) and pyrotinib (a targeted therapy), for people with HER2-positive breast cancer that has spread and has already been treated with an antibody-drug conjugate (ADC). The goal is to see if this combination can help control the cancer.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) before surgery for women with early-stage HER2-positive breast cancer. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests a treatment for early-stage HER2-positive breast cancer that is small and has not spread to lymph nodes. It aims to reduce the chance of cancer returning after surgery.
Hear when a new Breast Cancer Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.